Headline News
Asos losses widen, sales fall in first half but stock cuts ahead of target
Half-year losses at UK online fast-fashion retailer Asos have widened as it continued to deal with competition from Chinese rival Shein, but said it was ahead of target on shifting the mountain of excess stock it built up during the Covid pandemic.
Eli Lilly weight-loss drug 'significantly' reduces sleep apnoea
Eli Lily’s weight-loss drug tirzepatide has been shown to “significantly” reduce sleep apnoea severity, the US drugs giant said on Wednesday.
First-quarter bookings fall sharply at ASML
Shares in ASML Holding came under pressure on Wednesday, after the chip industry giant disappointed with its first-quarter trading update.
Royal Mail-owner rebuffs takeover approach
Shares in International Distribution Services soared on Wednesday, after it emerged that Czech billionaire Daniel Kretinsky had made a takeover approach for the Royal Mail owner.
Liontrust sees annual outflows top £6bn
Liontrust Asset Management reported annual outflows of more than £6bn on Wednesday, but struck an upbeat tone for the coming year.
Urban Logistics upbeat as rents strengthen
Urban Logistics REIT struck a confident tone on Wednesday, after rents rose by nearly a quarter in the last three months of the year.
Workspace Group reports resilient fourth quarter
Office space provider Workspace Group reported resilient customer demand in an update on Wednesday, having completed 343 new lettings in its fourth quarter and boasting a total annual rental value of £8. 7m.
Hunting reports rise in earnings, flags some cash challenges
Oil services provider Hunting said in a trading update on Wednesday that it had surpassed expectations for first-quarter EBITDA, which rose to $28. 9m from $22. 4m a year earlier, although it was facing challenges in managing its cash position.
GSK posts promising results from gonorrhoea treatment trial
GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid escalating resistance to current therapies.
Entain sees 'strong' performance in many markets during Q1
Entain reported an in line performance for its first quarter.